Mirtazapine in the Treatment of Panic Disorder
Available from: ncbi.nlm.nih.gov
The Primary Care Companion to The Journal of Clinical Psychiatry 05/2003; 5(2):93. DOI:10.4088/PCC.v05n0208
Expert Opinion on Pharmacotherapy 05/2005; 6(4):631-41. DOI:10.1517/146565126.96.36.1991 · 3.53 Impact Factor
Available from: Vladan Starcevic
[Show abstract] [Hide abstract]
ABSTRACT: OBJECTIVE: To review the most salient issues in the pharmacotherapy of anxiety disorders. These pertain to means of achieving greater efficacy, accelerating the onset of therapeutic action, improving side-effect profile and tolerability, decreasing the propensity to induce therapeutic dependence and achieving better long-term outcome. CONCLUSIONS: By and large, pharmacological agents with greater efficacy in anxiety disorders have yet to be developed. Several strategies have been used with some success to make medications for anxiety disorders work faster and to lessen their side-effect burden. The field of psychopharmacology has yet to find ways of lessening or eliminating the problem of therapeutic drug dependence and, even more so, of minimizing the risk of relapse following the cessation of medication.
Australasian Psychiatry 01/2006; 13(4):371-4. DOI:10.1111/j.1440-1665.2005.02225.x · 0.47 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.